365 related articles for article (PubMed ID: 32062536)
21. A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.
Knapen LM; Geurts SME; Ibragimova KIE; Croes S; Vriens BEPJ; van den Berkmortel FWPJ; Dercksen MW; van de Wouw AJ; Pepels MJAE; de Fallois AOJ; Lobbezoo DJA; de Boer M; Tjan-Heijnen VCG
Breast; 2019 Apr; 44():46-51. PubMed ID: 30641299
[TBL] [Abstract][Full Text] [Related]
22. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Bilici A; Uysal M; Menekse S; Akin S; Yildiz F; Turan M; Sezgin Goksu S; Beypinar I; Sakalar T; Değirmenci M; Erdem D; Basaran G; Olmez OF; Avci N; Tural D; Sakin A; Turker S; Demir A; Temiz S; Kaplan MA; Dogan M; Tanriverdi O; Bilgetekin I; Cinkir HY; Acikgoz O; Paydas S; Uslu R; Turhal S
Cancer Invest; 2022 Feb; 40(2):199-209. PubMed ID: 34894960
[TBL] [Abstract][Full Text] [Related]
23. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
24. Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
Oncologist; 2014 Apr; 19(4):346-7. PubMed ID: 24674873
[TBL] [Abstract][Full Text] [Related]
25. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
[TBL] [Abstract][Full Text] [Related]
26. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
27. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Ciruelos E; Jerusalem G; Martin M; Tjan-Heijnen VCG; Neven P; Gavila J; Montemurro F; Generali D; Lang I; Martínez-Serrano MJ; Perelló MF; Conte P
Clin Transl Oncol; 2020 Oct; 22(10):1857-1866. PubMed ID: 32170637
[TBL] [Abstract][Full Text] [Related]
28. Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR
Bardia A; Modi S; Oliveira M; Cortes J; Campone M; Ma B; Dirix L; Weise A; Hewes B; Diaz-Padilla I; Han Y; Deshpande P; Samant TS; Lorenc KR; He W; Su F; Chavez-MacGregor M
Clin Cancer Res; 2020 Dec; 26(24):6417-6428. PubMed ID: 32998962
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
Iwamoto T; Fujisawa T; Shien T; Araki K; Sakamaki K; Sangai T; Kikawa Y; Takao S; Nishimura R; Takahashi M; Aihara T; Mukai H; Taira N
Breast Cancer; 2020 Sep; 27(5):973-981. PubMed ID: 32394413
[TBL] [Abstract][Full Text] [Related]
30. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
32. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Beaver JA; Park BH
Future Oncol; 2012 Jun; 8(6):651-7. PubMed ID: 22764762
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Noguchi S; Masuda N; Iwata H; Mukai H; Horiguchi J; Puttawibul P; Srimuninnimit V; Tokuda Y; Kuroi K; Iwase H; Inaji H; Ohsumi S; Noh WC; Nakayama T; Ohno S; Rai Y; Park BW; Panneerselvam A; El-Hashimy M; Taran T; Sahmoud T; Ito Y
Breast Cancer; 2014 Nov; 21(6):703-14. PubMed ID: 23404211
[TBL] [Abstract][Full Text] [Related]
35. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
Dhillon S
Drugs; 2013 Apr; 73(5):475-85. PubMed ID: 23529824
[TBL] [Abstract][Full Text] [Related]
36. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
37. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Piccart M; Hortobagyi GN; Campone M; Pritchard KI; Lebrun F; Ito Y; Noguchi S; Perez A; Rugo HS; Deleu I; Burris HA; Provencher L; Neven P; Gnant M; Shtivelband M; Wu C; Fan J; Feng W; Taran T; Baselga J
Ann Oncol; 2014 Dec; 25(12):2357-2362. PubMed ID: 25231953
[TBL] [Abstract][Full Text] [Related]
38. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Kruger DT; Jansen MPHM; Konings IRHM; Dercksen WM; Jager A; Oulad Hadj J; Sleijfer S; Martens JWM; Boven E
Mol Oncol; 2020 Mar; 14(3):490-503. PubMed ID: 31841262
[TBL] [Abstract][Full Text] [Related]
39. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
40. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
